Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.

被引：4
|
作者：
Diaz, Luis A.
Le, Dung T.
Yoshino, Takayuki
Andre, Thierry
Bendell, Johanna C.
Koshiji, Minori
Zhang, Yinghua
Kang, S. Peter
Lam, Bao
Jaeger, Dirk
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.TPS3618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3618
引用
收藏
页数：6
相关论文
共 50 条
  • [1] KEYNOTE-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).
    Diaz, Luis A.
    Le, Dung T.
    Yoshino, Takayuki
    Andre, Thierry
    Bendell, Johanna C.
    Rosales, Minori
    Kang, S. Peter
    Lam, Bao
    Jager, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] KEYNOTE-177: First-line, open-label, randomized, phase 3 study of pembrolizumab versus investigator choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma
    Diaz, Luis A.
    Le, Dung T.
    Yoshino, Takayuki
    Andre, Thierry
    Bendell, Johanna C.
    Koshiji, Minori
    Zhang, Yinghua
    Kang, S. Peter
    Lam, Baohoang
    Jager, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] First-line pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma: randomized, phase 3 KEYNOTE-177 study
    Luis, Diaz
    Le Dung
    Takayuki, Yoshino
    Thierry, Andre
    Johanna, Bendell
    Minori, Koshiji
    Zhang Yinghua
    Peter, Kang S.
    Bao, Lam
    Dirk, Jaeger
    ANNALS OF ONCOLOGY, 2016, 27 : 80 - 80
  • [4] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase III KEYNOTE-177 study
    Shiu, K. K.
    Andre, T.
    Kim, T. W.
    Jensen, B. Vittrup
    Jensen, L. H.
    Punt, C. J. A.
    Smith, D.
    Garcia-Carbonero, R.
    Alcaide-Garcia, J.
    Gibbs, P.
    De la Fouchardiere, C.
    Rivera, F.
    Fernandez, M. E. Elez
    Le, D. T.
    Yoshino, T.
    Zuo, Y.
    Fogelman, D.
    Adelberg, D. E.
    Diaz, L. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1271 - S1272
  • [5] KEYNOTE-177: First-line, open-label, randomized, phase III study of pembrolizumab (MK-3475) versus investigator-choice chemotherapy for mismatch repair deficient or microsatellite instability-high metastatic colorectal carcinoma.
    Diaz, Luis A.
    Le, Dung T.
    Yoshino, Takayuki
    Andre, Thierry
    Bendell, Johanna C.
    Zhang, Yinghua
    Lam, Baohoang
    Koshiji, Minori
    Jager, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
    Andre, T.
    Amonkar, M.
    Norquist, J.
    Shiu, K-K.
    Kim, T. W.
    Jensen, B. V.
    Jensen, L. H.
    Punt, C. J.
    Smith, D.
    Garcia-Carbonero, R.
    Sevilla, I.
    de la Fouchardiere, C.
    Rivera, F.
    Elez, E.
    Diaz, L. A.
    Yoshino, T.
    Van Cutsem, E.
    Yang, P.
    Farooqui, M. Z. H.
    Le, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S409 - S409
  • [7] Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup
    Yoshino, T.
    Andre, T.
    Kim, T. W.
    Yong, W. P.
    Shiu, K-K.
    Jensen, B. Vittrup
    Jensen, L. H.
    Punt, C. J. A.
    Smith, D.
    Garcia-Carbonero, R.
    Alcaide-Garcia, J.
    Gibbs, P.
    de la Fouchardiere, C.
    Rivera, F.
    Elez Fernandez, M. E.
    Le, D. T.
    Zuo, Y.
    Fogelman, D.
    Adelberg, D. E.
    Diaz, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1502 - S1503
  • [8] Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
    Diaz, Luis A.
    Shiu, Kai-Keen
    Kim, Tae-Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis
    Smith, Denis
    Garcia-Carbonero, Rocio
    Benavides, Manuel
    Gibbs, Peter
    de la Fourchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David
    Marinello, Patricia
    Andre, Thierry
    LANCET ONCOLOGY, 2022, 23 (05): : 659 - 670
  • [9] Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis Michel
    Garcia-Carbonero, Rocio
    Alcaide, Julia
    Gibbs, Peter
    De la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Bendell, Johanna C.
    Le, Dung T.
    Yoshino, Takayuki
    Zhong, Wen Yan
    Fogelman, David R.
    Marinello, Patricia
    Diaz, Luis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Pembrolizumab (pembro) for previously treated, microsatellite instabilityehigh (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
    Le, D. T.
    Diaz, L.
    Kim, T. W.
    Van Cutsem, E.
    Geva, R.
    Jager, D.
    Hara, H.
    Burge, M.
    O'Neil, B.
    Kavan, P.
    Yoshino, T.
    Guimbaud, R.
    Taniguchi, H.
    Elez, E.
    Al-Batran, S-E.
    Boland, P.
    Cui, Y.
    Leconte, P.
    Marinello, P.
    Andre, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S550 - S550
12345